Skip to main content

Table 1 Patient characteristics

From: Efficacy of perioperative high-dose prednisolone therapy during thymectomy in myasthenia gravis patients

 

ph-PSL (n = 70)

Control (n = 61)

P-value

Age, years

46.9 ± 17.4

51.3 ± 13.9

0.115

Sex, n, male/female

21/49

20/41

0.732

Preoperative%FVC

92.4 ± 18.4

99.5 ± 18.9

0.037*

Preoperative FEV 1.0%

85.2 ± 10.2

81.4 ± 6.9

0.017*

Initial MGFA Class I/IIA/IIB/IIIA/IIIB, n

0/28/17/9/16

25/29/5/1/1

 

Initial MGFA Class I + IIA/IIB + IIIA + IIIB, n

28/42

54/7

<0.001*

Initial achR-Ab, nmol/l

62.5 ± 98.4

93.0 ± 310.3

0.456

Preoperative anti-ChE, yes/no

47/23

33/28

0.127

Preoperative tacrolimus, yes/no

3/67

0/61

0.248

Thymoma, yes/no

21/49

27/34

0.091

Surgical approach, thoracotomy /VATS

54/16

52/9

0.272

  1. *Statistically significant difference.
  2. Values represent mean ± standard deviation achR-Ab, acetylcholine receptor antibody; anti-ChE, anti-cholinesterase; FEV, forced expiratory volume; FVC, forced vital capacity; MGFA, Myasthenia Gravis Foundation of America; VATS, video-assisted thoracoscopic surgery.